---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003550"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:31:25.245013+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma Q1 net loss $3.5M; Berubicin GBM trial topline data H1 2025

## Summary
- Net loss $3.5M for Q1 2024, vs $4.9M in Q1 2023; R&D expense down to $2.4M from $3.6M.
- Cash at March 31, 2024 was ~$0.8M; no revenue reported.
- Enrollment completed in potentially pivotal Berubicin trial for GBM; DSMB recommended continuation in Dec 2023.
- Topline data from Berubicin study expected first half 2025.
- FDA granted Fast Track and Orphan Drug designations for Berubicin.

## SEC filing metadata
- accession: 0001683168-24-003550
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003550
- JSON: https://secwatch.observer/filing/0001683168-24-003550.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003550.txt

## Source-grounded claims
- claim_id: 8144647eedf7a0dd41310a000a10866b0e0a21f2
  claim: CNS Pharmaceuticals, Inc. reported the first quarter 2024 ended March 31, 2024 results: net income approximately $3.5 million, EPS $(0.34) per diluted share.
  evidence_excerpt: CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.